Is the Heron Therapeutics (HRTX) investment thesis intact?

It is under pressure. Readouts currently rates the Heron Therapeutics Thesis Challenged. Acute care growth must offset CINVANTI uncertainty as Heron weighs strategic alternatives.

What is the next catalyst for Heron Therapeutics (HRTX)?

The next dated event is Results for ZYNRELEF, expected Q1 2027, as stated by the company.

How long will Heron Therapeutics' cash last?

Heron Therapeutics has said its cash will fund operations beyond Aug 2027 (guidance as of August 10, 2026). It reported $42.7 million in cash as of June 30, 2026.

HRTXHeron Therapeutics, Inc.

ChallengedLast material event Aug 10, 2026 · Updated Oct 27, 2026

Acute care growth must offset CINVANTI uncertainty as Heron weighs strategic alternatives

Heron Therapeutics is a commercial-stage company selling ZYNRELEF for postoperative pain, APONVIE for postoperative nausea, and CINVANTI and SUSTOL for chemotherapy-induced nausea.

Heron's case rests on ZYNRELEF and APONVIE growing enough to offset pressure on CINVANTI, its largest product. The CINVANTI patent ruling and uncertain generic entry prompted withdrawn guidance, spending restraint and consideration of strategic alternatives. Acute care growth supports the transition, but funding depends on management's operating assumptions and credit covenants. The Long Grove license adds potential products and payment obligations; its commercial contribution remains to be clarified.

Thesis checklist

2 risks need attention

Select a row for evidence

What must be trueStateNext proof

CINVANTI keeps its market protectionAt riskAn appeal update and clarification of generic launch timing.Next: An appeal update and clarification of generic launch timing.

Why it is in this state

The evidence, what would weaken it and the source filing

ZYNRELEF and APONVIE keep growingSupportedThird-quarter product revenue at the November 9, 2026 results call.Next: Third-quarter product revenue at the November 9, 2026 results call.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash and the credit facility holdAt riskUpdated cash, covenant compliance and confirmation of the additional principal repayment.Next: Updated cash, covenant compliance and confirmation of the additional principal repayment.

Why it is in this state

The evidence, what would weaken it and the source filing

The strategic review finds a solutionAwaiting evidenceA strategic transaction announcement or fuller license economics and commercialization plans.Next: A strategic transaction announcement or fuller license economics and commercialization plans.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Can acute care sustain its growth?

Tests: ZYNRELEF and APONVIE keep growing

November 9, 2026, at 8:30 a.m. ET

Do ZYNRELEF and APONVIE sustain growth despite the paused sales force expansion?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentFinancial

-30.6%Aug 10, 2026

Acute care growth must offset CINVANTI uncertainty as Heron weighs strategic alternatives

ChallengedRegulatory

-45.8%Jun 2, 2026

ZYNRELEF's accelerating acute care growth must offset Cinvanti's patent-invalidated revenue base before generics erode the commercial foundation

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Postoperative pain management

ZYNRELEF · 1 upcoming

Data

2027Q1 2027

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Heron Therapeutics (HRTX) investment thesis intact?: It is under pressure. Readouts currently rates the Heron Therapeutics Thesis Challenged. Acute care growth must offset CINVANTI uncertainty as Heron weighs strategic alternatives.
What is the next catalyst for Heron Therapeutics (HRTX)?: The next dated event is Results for ZYNRELEF, expected Q1 2027, as stated by the company.
How long will Heron Therapeutics' cash last?: Heron Therapeutics has said its cash will fund operations beyond Aug 2027 (guidance as of August 10, 2026). It reported $42.7 million in cash as of June 30, 2026.

Disease areas: Neurology and pain, Liver and digestive diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

2 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.